Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML

Summary

In this open-label, randomized, prospective clinical trial, newly-diagnosed AML patients will be randomized into 2 groups. In the experimental arm, patients receive DA induction regimen with intermediate dose of cytarabine. In the control arm, patients receive DA regimen with standard dose of cytarabine.The efficacy of induction therapy containing intermediate dose of cytarabine is evaluated and adverse events associated with treatment are recorded.The primary end point is overall survival.

Timeline

Start

2017-02-08

Primary completion

2026-05-15

Completion

2027-10-15

Drugs

Indications